亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Zinc Oxide Nanoparticles Demonstrating Directed Cytotoxicity to Leukemia

技術優勢
ZnO-NPs exhibit a strong preferential ability to kill cancerous cells compared to healthy tissues. Key research findings show that ZnO-NPs induce toxicity in a cell-specific and proliferation-dependent manner, with rapidly dividing cells being the most susceptible and quiescent cells being the least sensitive. ZnO-NPs have the potential to be delivered directly to cancerous cells through the coupling to targeting ligands specific for cancer cell markers.
詳細技術說明
This technology is in early stage development. The nanoparticles cytotoxicity characteristics have been tested in vitro on multiple cell lines. Further development of this technology at Boise State is proceeding through testing of ZnO-NPs cytotoxic characteristics on other cancers cell lines. Attempts at improving their selective cytotoxicity are being made through modifications effecting reactive oxide formation and coupling with tumor-targeting ligands (monoclonal antibodies, peptides, and small molecules). Also, in vivo efficacy and safety studies are planned for the near future.
*Abstract
Even as knowledge of cancer at the molecular and nanometer level has improved, advances in more targeted treatments have been slow. The indiscriminate action of cytotoxic agents used for cancer therapy lead to systemic toxicity and adverse effects, such as bone marrow suppression, neurotoxicity, and cardiomyopathy. In an attempt to reduce side effects of cancer therapeutics, Boise State presents uniquely designed Zinc Oxide Nanoparticles (ZnO-NPs). These nanoparticles have demonstrated an increased cytotoxicity toward cancerous cell lines with relatively low effect on healthy tissues. The cytotoxicity is due to reactive oxide formation and subsequent cell death. ZnO-NPs elicit their cytotoxic effects 28-35 times higher on mammalian T-cell Leukemia cell lines in comparison to healthy body tissues. The preferential targeting of ZnO-NPs to cancerous cells is of substantial magnitude, especially in comparison to ex vivo indices reported for other commonly used chemotherapeutic agents using similar cell viability assays. For example, therapeutic indices of Γëñ10 have been reported for both doxorubicin and carboplatin.
*Principal Investigation

Name: Madhusudan Kongara

Department:


Name: Alex Punnoose, Professor

Department: Physics


Name: Denise Wingett, Professor/Director/Biomolecular PhD Program

Department: Biological Sciences

附加資料
Inventor: Punnoose, Alex | Kongara, Madhusudan R. | Wingett, Denise
Priority Number: US8187638B2
IPC Current: A61K000914 | A61K003308 | A61K003330
US Class: 424489 | 42400133 | 42400161 | 4241551 | 424490 | 424641 | 514494
Assignee Applicant: Boise State University,Boise
Title: Preferential killing of cancer cells and activated human T cells using ZnO nanoparticles
Usefulness: Preferential killing of cancer cells and activated human T cells using ZnO nanoparticles
Summary: The methods are useful for preferentially killing cancer cells over normal cells and for preferentially killing activated T cells over unactivated T cells. Specifically, the methods are used for treating cancer and autoimmune diseases (all claimed). The nanoparticles are particularly used for inducing apoptosis in reactive oxygen species (ROS)-generating cancerous T cells.
Novelty: Preferentially killing cancer cells relative to normal cells comprises treating the cells with zinc oxide nanoparticles
主要類別
診斷/治療
細分類別
癌症/腫瘤
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備